Individuals with type 2 diabetes mellitus (T2D) and/or non-alcoholic fatty liver disease (NAFLD) exhibit hepatic glucagon resistance [3,4], which in turn contributes to worsening of steatosis by blocking the beneficial effects of glucagon on hepatic fat. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.